Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients

Neuroscience Letters

Volumn 487, Issue 2, 2011, Pages 134-138

  Kandimalla, Ramesh JL ^a   S, Prabhakar ^a   BK, Binukumar ^a   Wani, Willayat Yousuf ^a   Sharma, Deep Raj ^a   Grover, V K ^a   Bhardwaj, Neerja ^a   Jain, Kajal ^a   Gill, Kiran Dip ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

A 42; Alzheimer's disease; HTau; North Indian population; Ubiquitin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; UBIQUITIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM ATROPHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMYELINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MENINGITIS; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINAL CORD DISEASE; UBIQUITINATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DOWN-REGULATION; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TAU PROTEINS; UBIQUITIN; UP-REGULATION;

EID: 78650187839     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.075     Document Type: Article

References (52)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., Blennow K. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 1999, 273:5-8.
3. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 2001, 58:373-379.
4. Bond U., Schlesinger M.J. Ubiquitin is a heat shock protein in chicken embryo fibroblasts. Mol. Cell. Biol. 1985, 5:949-956.
5. Bond U., Schlesinger M.J. The chicken ubiquitin gene contains a heat shock promoter and expresses an unstable mRNA in heat-shocked cells. Mol. Cell. Biol. 1986, 6:4602-4610.
6. Bramblett G.T, Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10:1089-1099.
7. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
8. Chandra V., Pandav R., Dodge H.H., Johnston J.M., Belle S.H., DeKosky S.T., Ganguli M. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 2001, 57:985-989.
9. Clark C.M, Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel D.W., Farlow M., Weitlauf S.L., Quinn J., Kaye J., Knopman D., Arai H., Doody R.S., DeCarli C., Leight S., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol. 2003, 60:1696-1702.
10. Dickson D.W., Wertkin A., Kress Y., Ksiezak-Reding H., Yen S.H. Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. Lab. Invest. 1990, 63:87-99.
11. Doherty F.J., Osborn N.U., Wassell J.A., Heggie P.E., Laszlo L., Mayer R.J. Ubiquitin-protein conjugates accumulate in the lysosomal system of fibroblasts treated with cysteine proteinase inhibitors. Biochem. J. 1989, 263:47-55.
12. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
13. Formichi P., Battisti C., Radi E., Federico A. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J. Cell. Physiol. 2006, 208:39-46.
14. Galasko D. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. J. Neural Transm. Suppl. 1998, 53:209-221.
15. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., DeKosky S.T., Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National Dementia Study. Arch. Neurol. 2000, 57:824-830.
16. Hershko A., Ciechanover A. The ubiquitin pathway for the degradation of intracellular proteins. Prog. Nucleic Acid Res. Mol. Biol. 1986, 33:301. 19-56.
17. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2000, 2:199-206.
18. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555-1562.
19. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C.L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 1996, 271:22908-22914.
20. Jarrett J.T., Berger E.P., Lansbury P.T. The C-terminus of the beta protein is critical in amyloidogenesis. Ann. N.Y. Acad. Sci. 1993, 695:144-148.
21. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.O., Werle E., Jauss M., Beyreuther K., Lannfelt L., Hartmann T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 1999, 45:504-511.
22. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1550-1555.
23. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 1998, 44:17-26.
24. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
25. Kudo T., Iqbal K., Ravid R., Swaab D.F., Grundke-Iqbal I. Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 1994, 639:1-7.
26. Leigh P.N., Probst A., Dale G.E., Power D.P., Brion J.P., Dodson A., Anderton B.H. New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol. 1989, 79:61-72.
27. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25:273-281.
28. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
29. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., Mayer R.J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 1988, 155:9-15.
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
31. Monia B.P., Ecker D.J., Finley D., Crooke S.T. A human ubiquitin carboxyl extension protein functions in yeast. J. Biol. Chem. 1990, 265:19356-19361.
32. Mori H., Kondo J., Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 1987, 235:1641-1644.
33. Motter R, Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38:643-648.
34. Noguchi M., Yoshita M., Matsumoto Y., Ono K., Iwasa K., Yamada M. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 2005, 237:61-65.
35. Parag H.A., Raboy B., Kulka R.G. Effect of heat shock on protein degradation in mammalian cells: involvement of the ubiquitin system. EMBO J. 1987, 6:55-61.
36. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3033-3036.
37. Rechsteiner M. Ubiquitin-mediated pathways for intracellular proteolysis. Annu. Rev. Cell Dev. Biol. 1987, 3:1-30.
38. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 1996, 212:209-211.
39. Riemenschneider M., Schmolke M., Lautenschlager N., Guder W.G., Vanderstichele H., Vanmechelen E., Kurz A. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 2000, 284:85-88.
40. Samuels S.C., Silverman J.M., Marin D.B., Peskind E.R., Younki S.G., Greenberg D.A., Schnur E., Santoro J., Davis K.L. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 1999, 52:547-551.
41. Schroder J, Pantel J., Ida N., Essig M., Hartmann T., Knopp M.V., Schad L.R., Sandbrink R., Sauer H., Masters C.L., Beyreuther K. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol. Psychiatry 1997, 2:505-507.
42. Shaji S., Bose S., Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br. J. Psychiatry 2005, 186:136-140.
43. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Hirai S. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998, 158:134-140.
44. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
45. Subramanian S., Sandhyarani B., Shree A.N., Murthy K.K., Kalyani K., Kumar S.P., Pradeep, Noone M.J., Taly A.B. Lower levels of cerebrospinal fluid amyloid beta (Abeta) in non-demented Indian controls. Neurosci. Lett. 2006, 407:121-123.
46. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., Cohen R.M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 2004, 56:670-676.
47. Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., Hirai S., Furiya Y., Endoh R., Mori H. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Sci. 1997, 148:41-45.
48. Tapiola T., Pirttila T., Mehta P.D., Alafuzofff I., Lehtovirta M., Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol. Aging 2000, 21:735-740.
49. Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., Pirttila T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009, 66:382-389.
50. Vas C.J., Pinto C., Panikker D., Noronha S., Deshpande N., Kulkarni L., Sachdeva S. Prevalence of dementia in an urban Indian population. Int. Psychogeriatr. 2001, 13:439-450.
51. Wang G.P., Khatoon S., Iqbal K., Grundke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res. 1991, 566:146-151.
52. Blennow K., Davidsson P., Wallin A., Gottfries C.G., Svennerholm L. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int. Psychogeriatr. 1994, 6:13-22. discussion 59-60.